Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021)
Mesoblast (MESO) posted Non-Current Deferred Tax Liability of $80.2 million for Q4 2021, little changed sequentially from $80.2 million in Q3 2021, and little changed YoY from $80.1 million in Q4 2020.
Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends
Mesoblast has reported Non-Current Deferred Tax Liability for 7 years, with the latest figure at $80.2 million in Q4 2021.
- Quarterly Non-Current Deferred Tax Liability changed 0.11% year-over-year to $80.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $80.2 million (changed 0.11% YoY) and the FY2021 annual result came in at $80.2 million, up 10881.37% from the prior year.
- Non-Current Deferred Tax Liability was little changed at $80.2 million in Q4 2021 per MESO's latest filing, from $80.2 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $80.2 million in Q3 2021 and troughed at $730000.0 in Q2 2020.
- A 5-year average of $45.0 million and a median of $47.8 million in 2017 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2020 and 2021: Non-Current Deferred Tax Liability plunged 99.05% in 2020, then soared 10881.37% in 2021.
- Over 5 years, Non-Current Deferred Tax Liability stood at $23.9 million in 2017, then tumbled by 30.98% to $16.5 million in 2018, then plunged by 58.06% to $6.9 million in 2019, then soared by 1057.43% to $80.1 million in 2020, then grew by 0.11% to $80.2 million in 2021.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $80.2 million, $80.2 million, and $80.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 80.21 Mn |
| Dec 31, 2021 | 80.21 Mn |
| Sep 30, 2021 | 80.25 Mn |
| Sep 30, 2021 | 80.25 Mn |
| Jun 30, 2021 | 80.16 Mn |
| Jun 30, 2021 | 80.16 Mn |
| Mar 31, 2021 | 80.20 Mn |
| Mar 31, 2021 | 80.20 Mn |
| Dec 31, 2020 | 80.12 Mn |
| Dec 31, 2020 | 80.12 Mn |
| Sep 30, 2020 | 79.91 Mn |
| Sep 30, 2020 | 79.91 Mn |
| Jun 30, 2020 | 730,000.00 |
| Jun 30, 2020 | 730,000.00 |
| Mar 31, 2020 | 4.97 Mn |
| Mar 31, 2020 | 4.97 Mn |
| Dec 31, 2019 | 6.92 Mn |
| Dec 31, 2019 | 6.92 Mn |
| Sep 30, 2019 | 9.20 Mn |
| Sep 30, 2019 | 9.20 Mn |